Vedanta Biosciences Announces $25Million Investment from Pfizer Inc.
A leading clinical-stage company developing a new category of therapies for immune-mediated diseases basedon rationally defined consortia of human microbiome-derived bacteria,...
Search
All
A leading clinical-stage company developing a new category of therapies for immune-mediated diseases basedon rationally defined consortia of human microbiome-derived bacteria,...
Seventure Partners, one of Europe’s leaders in financing innovation and a world leader in life science microbiome investment, has increased focus on skin microbiome...
Pioneering a full-ecosystem microbiota approach to improve survival outcomes in life-threatening diseases by Hervé Affagard (Maat Pharma) published on...
The leading Brand Performance Cloud for the Fashion, Luxury & Beauty (FLB) industries, announces the acquisition of PARKLU, China’s premier influencer analytics platform.
MaaT Pharma announced today that it treated its first patient in a Phase 1 clinical trial to evaluate the safety and tolerability of MaaT033, a capsule formulation of the...
A consumer dermatology company developing novel, personalized, microbiome-based solutions for acne and other skin conditions, announced today that it has closed a $6.73 million...